# A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas

Source: https://onco.cc/trials/nct06679101/  
OnCo record `nct06679101` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Belantamab mafodotin, Lenalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) is a phase 3 interventional study registered as NCT06679101 by GlaxoSmithKline, with 520 participants planned, started 2024-12-16 and due to reach its primary completion in 2031-04-28. Interventions recorded: Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab. Conditions listed: Multiple Myeloma, Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06679101
- Phase: 3
- Setting: A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Sponsor: GlaxoSmithKline
- Enrolled: 520

## Sources

- ClinicalTrials.gov NCT06679101: https://clinicaltrials.gov/study/NCT06679101

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06679101.json